RGEN Q2 FY2026 earnings call — BigGo Finance
Repligen (RGEN) reported Q2 FY2026 revenue of $204M, up 12% reported and 13% organic. Adjusted EPS rose 46% to $0.54, with adjusted gross margin up 280 bps to 53.9% and operating margin up 460 bps to 16.7%. The company raised full-year guidance to $2.03-$2.09 adjusted EPS and expects 10.5%-13.5% organic growth, citing order momentum and Proteins/Analytics strength. It also agreed to acquire BioLife, expected to close in Q4 2026.
How this was made
The 30-second read
Why it matters
Traders can reprice the stock based on the raised FY2026 organic growth and adjusted EPS range, plus updated margin cadence commentary (Q3 gross margin lowest of the year, Q4 benefits from volume leverage). The BioLife deal adds a forward catalyst but also execution risk into Q4 2026.
Market read
Raised guidance with specific EPS and organic growth targets, plus margin expansion and a definitive acquisition agreement, are the primary drivers for near-term positioning.
What to watch
BioLife is expected to close in Q4 2026 with stated synergies, but integration timing and customer conversion (especially capital equipment plant readiness) could delay the expected margin and EPS lift.
Background
This is Repligen’s Q2 FY2026 earnings call summary, including raised full-year guidance and a definitive agreement to acquire BioLife (cell therapy biopreservation).
Ticker impact
Repligen raised FY2026 organic growth to 10.5%-13.5% and adjusted EPS to $2.03-$2.09, citing order momentum and margin expansion.
Bias upward for the next few sessions, with volatility around filtration recovery assumptions and BioLife deal execution into Q4 2026.
The article provides specific, time-sensitive guidance updates and margin/EPS figures from the earnings call, plus a definitive acquisition agreement expected to close in Q4 2026.
Market effects
Signals improving demand in bioprocessing tools and consumables (Proteins and Analytics strength) while highlighting filtration softness tied to gene therapy and ATF customer readiness.
APAC acceleration (APAC +40%, China +60% in H1) suggests regional demand divergence that could affect peers’ regional order expectations.
BioLife acquisition framing supports continued consolidation and cell-therapy biopreservation investment themes in the broader bioprocessing supply chain.
Counterpoint
Filtration remains the laggard with multiple headwinds, so the raised consolidated outlook may prove sensitive if ATF and gene-therapy normalization slips.
Key entities
- companyRepligen Corporation
Reported Q2 FY2026 results, raised FY2026 guidance, and announced a definitive BioLife acquisition agreement expected to close in Q4 2026.
- acquisition_targetBioLife
Cell therapy biopreservation platform to be acquired by Repligen, with stated year-one and year-two synergy targets.
